Abstract Library

#2004 OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

Introduction: OPALINE Study focuses on patients with pNET. 2 targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Lombard-Bohas C, Lepage C, Vicaut E, Dominguez S, Coriat R,

Keywords: pNET, targeted therapies,

#1842 OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET).

Introduction: OPALINE Study focuses on patients with pNET. Two targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lombard-Bohas V

Authors: Lombard-Bohas C, Lepage C, Vicaut E, Dominguez S, Coriat R,

Keywords: pNET, targeted therapy,

#1637 The Effect of the Autophagy Inhibitor Chloroquine (CQ), Alone or in Combination with mTOR Inhibitors, on Neuroendocrine Tumor (NET) Growth and Metastatic Spread in Mouse Models

Introduction: mTOR inhibitors (mTORi) such as RAD001 demonstrated promising anti-cancer effect in NETs. Autophagy, a cell survival mechanism, is activated by mTORi. We have recently shown in the human NET cell line BON1 that autophagy is essential for cell survival. Treatment with CQ alone or together with mTORi robustly inhibited cell proliferation and survival, suggesting that treatment with CQ may potentiate the anti-tumorigenic effects of mTORi.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Leibowitz G, Gross D, Grozinsky-Glasberg S,

Keywords: autophagy, mTORi, NET,

#1036 Abrogation of Autophagy by Chloroquine in Neuroendocrine Tumor Cells Treated with mTOR Inhibitors Induces Apoptosis, While Reduction of Cell Proliferation is Due to a Chloroquine, Autophagy Unrelated, Lysosomal Effect

Introduction: The therapy options for patients with advanced NETs are limited. The mTOR inhibitors (mTORi), Torin1 and NVP-BEZ235, are known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to prolong survival, evading the anti-cancer effect. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to inhibit autophagy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Avniel- Polak S

Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Grozinsky-Glasberg S,

Keywords: NETs, autophagy, mTORi ,

#919 Effect of Combined Treatment with mTOR Inhibitors (mTORi) and Dopamine Agonists on Cell Proliferation in a Human Typical Lung Carcinoid Cell Line

Introduction: The mTOR pathway and dopamine receptors are potential targets for treatment of neuroendocrine tumors (NET).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Sarnataro M

Authors: Sarnataro M, Pivonello C, De Martino M, Sciammarella C, Cuomo G,

Keywords: mTOR, dopamine,